Drugs Containing Excipient (Inactive Ingredient) SUCROSE DISTEARATE

Branded drugs containing SUCROSE DISTEARATE excipient, and estimated key patent expiration / generic entry dates

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Haleon US Holdings LLC	ABREVA	docosanol	0135-0200	SUCROSE DISTEARATE
A-S Medication Solutions	ABREVA	docosanol	50090-3476	SUCROSE DISTEARATE

Generic drugs containing SUCROSE DISTEARATE excipient

Company	Ingredient	NDC	Excipient
Haleon US Holdings LLC	docosanol	0135-0200	SUCROSE DISTEARATE
Haleon US Holdings LLC	docosanol	0135-0300	SUCROSE DISTEARATE
Walgreens	docosanol	0363-2981	SUCROSE DISTEARATE
Walgreens	docosanol	0363-6510	SUCROSE DISTEARATE
Walgreens	docosanol	0363-8877	SUCROSE DISTEARATE

Sucrose Distearate Market Dynamics, Regulatory Status, Patent Landscape, and Financial Outlook

Last updated: September 18, 2026

Sucrose distearate is a specialty sucrose fatty-acid ester used primarily as a nonionic emulsifier, solubilizer, wetting agent, and texture modifier. Its commercial market is small relative to major pharmaceutical excipients such as microcrystalline cellulose, lactose, povidone, and polysorbates. Public companies generally do not report sucrose distearate revenue separately, so the financial trajectory must be assessed through end-market demand, regulatory acceptance, supplier concentration, raw-material costs, and substitution risk.

The strongest demand drivers are oral formulations, nutraceuticals, cosmetics, food emulsification, and selected controlled-release or lipid-based delivery systems. Pharmaceutical growth is likely to remain gradual rather than high-growth because formulators often select broader sucrose ester grades, sucrose stearate mixtures, polysorbates, poloxamers, lecithin, or PEG-based surfactants instead of the discrete distearate molecule.

What is sucrose distearate and how is it used?

Sucrose distearate is an ester of sucrose and stearic acid containing two stearoyl groups. It belongs to the broader sucrose fatty-acid ester family, which includes monoesters, diesters, triesters, and higher substitution levels.

Attribute	Sucrose distearate
Chemical class	Sucrose fatty-acid ester
Primary fatty acid	Stearic acid
Degree of esterification	Diester
Typical function	Emulsifier, surfactant, solubilizer, wetting agent
Physical form	Solid or waxy material, depending on grade and composition
Key quality variables	Degree of esterification, fatty-acid profile, moisture, acid value, hydroxyl value, HLB
Main end markets	Food, cosmetics, nutraceuticals, pharmaceuticals
Common regulatory issue	Product-specific grade and composition determine suitability

Commercial products may not be chemically identical to a high-purity sucrose distearate. Suppliers often sell sucrose stearate or sucrose ester blends containing monoesters, diesters, and higher esters. Those mixtures can have different hydrophilic-lipophilic balance values and different performance in emulsions, tablets, creams, and lipid systems.

The distinction matters commercially. A formulation patent or supplier specification covering “sucrose fatty-acid esters” may capture a broader technical class but may not provide exclusivity over sucrose distearate itself. Conversely, a buyer seeking a reproducible pharmaceutical grade may accept only a narrow composition range.

What are the main pharmaceutical applications of sucrose distearate?

Sucrose distearate is most relevant where the formulation requires interfacial activity rather than bulk tablet binding or disintegration.

Oral emulsions and lipid-based formulations

Sucrose esters can stabilize oil-in-water systems and improve wetting or dispersion of poorly water-soluble ingredients. Potential applications include oral liquids, lipid-based delivery systems, soft-gel fills, and nutraceutical emulsions.

The commercial opportunity depends on whether the product is used as a primary emulsifier or as a supporting surfactant. Primary emulsifier applications generally require tighter control of HLB and batch-to-batch composition.

Solid oral dosage forms

Sucrose esters can function as wetting agents, lubricity modifiers, or processing aids. Use in tablets and granules is more limited than use in food and cosmetics because pharmaceutical manufacturers prioritize established compendial excipients with extensive toxicology and regulatory histories.

Topical and dermatological formulations

The molecule can support emulsification and skin-product texture. Topical pharmaceutical demand is possible, but competition includes glyceryl stearates, polysorbates, sorbitan esters, lecithin, poloxamers, and nonionic ethoxylates.

Modified-release and particulate systems

Sucrose esters may be incorporated into lipid matrices, microparticles, or other delivery systems. These uses are technically attractive but tend to be formulation-specific. Volumes are usually small, and commercial adoption can be delayed by scale-up and regulatory comparability requirements.

What is the regulatory status of sucrose distearate?

Sucrose fatty-acid esters have established regulatory use in food and cosmetic products, but food authorization does not automatically establish pharmaceutical excipient approval.

In the United States, sucrose fatty-acid esters are recognized under the food-additive framework when used within the applicable specifications and conditions of use. The relevant regulatory category is generally associated with sucrose esters of fatty acids rather than a single, isolated distearate substance. FDA’s Inactive Ingredient Database must be reviewed by exact ingredient name, route, dosage form, and maximum potency before relying on an existing pharmaceutical-use precedent.[1][2]

In Europe, sucrose esters of fatty acids are associated with the food additive designation E473. Pharmaceutical use remains dependent on the individual substance, the supplier’s quality documentation, and the marketing authorization dossier.[3]

Regulatory area	Assessment
Food use	Established for sucrose esters of fatty acids under applicable specifications
Cosmetic use	Broad international use as an emulsifier and surfactant
U.S. pharmaceutical use	Requires route- and dosage-form-specific assessment; exact distearate status must be distinguished from broader sucrose stearate entries
European pharmaceutical use	Requires dossier-specific justification and quality control
Compendial position	Depends on the applicable USP-NF, Ph. Eur., or supplier specification
Novel excipient status	Not generally treated as a new molecular excipient where an established sucrose ester precedent applies

For pharmaceutical commercialization, the key documents are the certificate of analysis, residual solvents profile, elemental impurities assessment, microbial limits, allergen statement, TSE/BSE statement, stability data, and change-control history. The degree of esterification and fatty-acid distribution should be controlled because they can affect performance.

What patents protect sucrose distearate?

Sucrose distearate is not generally protected by a single dominant composition-of-matter patent. The molecule is an established sucrose ester, and broad foundational composition claims are unlikely to create meaningful current exclusivity for the ingredient itself.

The relevant patent categories are narrower:

Patent category	Commercial relevance
Manufacturing process patents	Can cover esterification catalysts, solvent systems, purification, crystallization, or reaction control
Composition patents	May cover specified monoester/diester/higher-ester ratios or purity ranges
Formulation patents	May claim a drug product containing sucrose esters with defined HLB or concentration
Method-of-use patents	May cover use in emulsification, dissolution enhancement, topical delivery, or modified release
Supplier process know-how	Often more important than publicly enforceable ingredient patents
Packaging and stability patents	May cover moisture control, solid dispersions, or storage systems

The practical IP barrier is usually formulation and process know-how rather than the use of sucrose distearate as a standalone excipient. A formulation patent can restrict a particular combination of active ingredient, sucrose ester, concentration, particle size, or delivery system even when the excipient itself is widely available.

No meaningful Orange Book exclusivity attaches to sucrose distearate as an excipient. Orange Book listings are tied to approved drug products and their associated patents, not to independent excipient ownership.[4]

How many patents cover sucrose distearate?

There is no reliable public basis for assigning a single patent count to sucrose distearate. Search results vary substantially depending on whether the search includes:

• “sucrose distearate”
• “sucrose stearate”
• “sucrose esters of fatty acids”
• “sucrose fatty acid ester”
• “sucrose ester emulsifier”
• formulations that list the ingredient among many excipients

A defensible freedom-to-operate review must separate expired foundational patents from active process and formulation claims. It must also distinguish patents that merely list sucrose esters from patents that require sucrose distearate as a limiting element.

The likely patent position is therefore:

1. Low standalone composition-of-matter risk.
2. Moderate process risk where a supplier uses proprietary esterification or purification technology.
3. Moderate formulation risk in specialized drug-delivery systems.
4. Low risk from Orange Book patents unless the excipient is used in a patented approved product.

When does sucrose distearate lose exclusivity?

Sucrose distearate does not have a conventional drug exclusivity date. It is an excipient rather than a new active pharmaceutical ingredient.

There is no standard Hatch-Waxman exclusivity period, no independent New Chemical Entity exclusivity, and no biosimilar exclusivity framework for the excipient. Any relevant patent protection would expire according to the specific patent’s filing and priority dates, generally 20 years from the earliest effective nonprovisional filing date in the United States, subject to patent-term adjustment or other statutory changes.[5]

A supplier may retain commercial differentiation after patent expiry through:

• pharmaceutical-grade specifications;
• manufacturing scale;
• regulatory documentation;
• validated supply history;
• customer qualification;
• narrow HLB or ester-distribution control;
• technical support;
• supply agreements.

Those advantages are commercial barriers, not statutory exclusivity.

What generic entry risks exist for products using sucrose distearate?

Generic entry risk is product-specific. The presence of sucrose distearate does not independently block generic competition.

A generic applicant may need to match or sufficiently reproduce the reference product’s formulation performance, including dissolution, emulsion stability, particle size, release profile, and impurity profile. The excipient can become strategically important when it affects bioavailability or release behavior.

Product characteristic	Generic-entry effect
Sucrose distearate used as a minor processing aid	Usually low barrier
Sucrose distearate used as the primary emulsifier	Moderate formulation-development barrier
Narrow HLB requirement	Higher risk of failed formulation matching
Lipid-based delivery system	Potentially significant bioequivalence risk
Modified-release matrix	Possible formulation and patent risk
Supplier-specific grade	Qualification and supply-chain risk
Excipient listed in an Orange Book patent claim	Product-specific litigation risk

Paragraph IV challenges can arise against patents covering the finished drug product, formulation, method of treatment, or delivery system. They do not normally challenge “ownership” of sucrose distearate itself. The Hatch-Waxman litigation analysis must therefore focus on the approved drug product and its listed patents.[4]

Which companies supply sucrose distearate or related sucrose esters?

The supply base is fragmented between specialty sucrose-ester manufacturers, food-ingredient companies, cosmetic-ingredient suppliers, and pharmaceutical excipient distributors. Commercial names often refer to sucrose stearate or sucrose ester blends rather than isolated sucrose distearate.

Relevant supplier groups may include companies associated with:

• sucrose ester production;
• food emulsifiers;
• cosmetic surfactants;
• pharmaceutical excipient distribution;
• contract manufacturing of specialty esters.

Sisterna is a recognized supplier of sucrose esters for food, cosmetic, and technical applications. Mitsubishi Chemical Group has also marketed sucrose ester products and related specialty materials. Other suppliers may sell comparable grades through regional distributors rather than direct pharmaceutical channels.[6][7]

Supplier qualification should assess whether the product is:

1. a defined sucrose distearate;
2. a sucrose stearate blend;
3. a food-grade sucrose ester;
4. a cosmetic grade;
5. a pharmaceutical-grade excipient with validated change control.

The distinction affects dossier acceptance, batch reproducibility, and substitution rights.

How does sucrose distearate compare with competing excipients?

Excipient	Primary advantage	Main limitation versus sucrose distearate
Polysorbate 20 or 80	Extensive pharmaceutical use and strong regulatory familiarity	Oxidation, hydrolysis, and peroxide concerns
Poloxamer 188 or 407	Broad use in solubilization and biologics	Different thermal and micellar behavior
Lecithin	Natural-origin positioning and lipid compatibility	Variable composition and oxidation sensitivity
Sorbitan esters	Strong lipophilic emulsification	Lower hydrophilicity in some systems
Glyceryl stearate	Low cost and broad topical use	Less suitable for some aqueous emulsions
PEG-based surfactants	Established formulation performance	Potential impurity and degradation considerations
Sucrose distearate	Nonionic surfactant with adjustable ester composition	Smaller pharmaceutical evidence base and possible grade variability

Sucrose distearate is most competitive where a formulator wants a sugar-derived, nonionic emulsifier with a specific balance of hydrophilic and lipophilic behavior. It is less competitive where regulatory precedent, global supply depth, or biologics experience is the main selection criterion.

What manufacturing and supply-chain barriers affect the market?

Manufacturing requires controlled esterification of sucrose and stearic acid or stearic-acid-rich feedstocks. Important process variables include temperature, catalyst system, water removal, reaction time, degree of esterification, and purification.

The main cost inputs are:

• sucrose;
• stearic acid;
• energy;
• solvents or processing aids;
• purification;
• analytical testing;
• packaging;
• compliance and quality systems.

Raw-material volatility is more likely to affect margin than demand volatility in a small specialty market. Food-grade and cosmetic-grade capacity can support volume, but pharmaceutical customers require additional documentation and validation.

Supply risk is highest where:

• only one or two suppliers meet the customer’s specification;
• the supplier sells a proprietary ester distribution;
• the grade is imported;
• the ingredient is used in a registered drug product;
• the buyer has not qualified an alternate source.

Manufacturing patents may matter less than undocumented process know-how. The ability to reproduce a target HLB, impurity profile, and ester distribution at scale can be a stronger competitive advantage than a broad patent claim.

What is the financial trajectory for sucrose distearate?

Public financial reporting does not typically disclose revenue, gross margin, capacity, or backlog for sucrose distearate as a separate product. The molecule should therefore be analyzed as a specialty excipient within the broader sucrose ester and emulsifier markets.

The likely financial profile is:

Financial factor	Expected effect
Pharmaceutical adoption	Positive but gradual
Food and nutraceutical demand	Larger volume base
Cosmetic demand	Supports diversification
Raw-material prices	Direct margin pressure
Supplier qualification	Supports customer retention
Product substitution	Limits pricing power
Pharmaceutical-grade documentation	Supports premium pricing
Single-source status	Can increase pricing power but raises customer resistance
Dedicated capacity	Difficult to justify without anchor contracts

Revenue growth is likely to come from new formulations and geographic expansion rather than sharply increasing unit prices. Pharmaceutical customers may pay a premium for documentation and supply reliability, but the active ingredient generally determines most of the drug product’s value. That limits the excipient supplier’s ability to capture drug-level economics.

A realistic commercial trajectory is a low-to-mid single-digit growth profile for mature applications, with higher growth possible in selected lipid-delivery, nutraceutical, and clean-label formulation segments. This is a market assessment, not a reported market-size estimate. Product-level revenue forecasts are not publicly auditable.

What litigation and settlement activity affects sucrose distearate?

There is no established public litigation pattern in which sucrose distearate itself is the central patent dispute. Litigation risk is more likely to arise from:

• a finished pharmaceutical product using the excipient;
• a formulation patent claiming a specific emulsifier system;
• a process patent covering manufacture;
• a supplier contract or quality dispute;
• trade-secret allegations involving esterification or purification.

Settlement agreements in generic litigation would normally concern the approved drug product and its patents. They would not create a general market-wide settlement restricting sucrose distearate sales.

What is the commercial outlook for sucrose distearate?

Sucrose distearate has a viable specialty-excipient position, but it is unlikely to become a large standalone pharmaceutical market. Its strongest commercial attributes are formulation flexibility, nonionic behavior, sugar-derived positioning, and compatibility with emulsified or lipid-based systems.

Its constraints are limited product-specific disclosure, competition from established surfactants, variable commercial definitions, and the absence of a broad pharmaceutical exclusivity moat.

Key Takeaways

• Sucrose distearate is a specialty sucrose fatty-acid ester, not a conventional drug substance.
• The largest commercial base is likely food, cosmetics, and nutraceuticals, with pharmaceutical demand representing a smaller but higher-value segment.
• Public companies do not generally disclose sucrose distearate revenue separately.
• There is no independent Orange Book exclusivity or biosimilar framework for the ingredient.
• Patent risk is concentrated in manufacturing processes and finished-product formulations.
• Supplier grade, ester distribution, HLB, and pharmaceutical documentation determine commercial value.
• The most credible growth opportunities are lipid-based delivery, oral emulsions, topical products, and clean-label formulations.
• Substitution by polysorbates, lecithin, poloxamers, sorbitan esters, and glyceryl stearates limits pricing power.
• Generic-entry risk depends on the approved product’s formulation and listed patents, not on sucrose distearate alone.
• The financial outlook is stable but specialized, with gradual adoption rather than blockbuster-scale expansion.

FAQs about sucrose distearate

Is sucrose distearate the same as sucrose stearate?

No. Sucrose stearate is often a commercial mixture containing monoesters, diesters, and higher esters. Sucrose distearate refers more specifically to the diester component.

Is sucrose distearate safe for pharmaceutical use?

Use depends on route, dosage form, specification, exposure level, and regulatory documentation. Food or cosmetic authorization does not automatically establish pharmaceutical acceptability.

Is sucrose distearate listed in the FDA Inactive Ingredient Database?

The relevant FDA review must distinguish exact sucrose distearate from broader sucrose stearate or sucrose fatty-acid ester entries. Route, dosage form, and maximum potency control the significance of any listing.

Can a generic drug use a different sucrose ester supplier?

Usually, but the applicant must demonstrate that the alternative grade does not adversely affect product quality, bioequivalence, dissolution, stability, or release performance.

Does sucrose distearate have biosimilar competition?

No. Biosimilar competition applies to biological reference products. Sucrose distearate is a chemical excipient and is instead exposed to supplier substitution and formulation-level competition.

References

1. U.S. Food and Drug Administration. (n.d.). Inactive Ingredient Database. https://www.accessdata.fda.gov/scripts/cder/iig/index.cfm

2. U.S. Food and Drug Administration. (2023). 21 C.F.R. § 172.859: Sucrose fatty acid esters. https://www.ecfr.gov/current/title-21/section-172.859

3. European Commission. (n.d.). EU food additive database: E473 sucrose esters of fatty acids. https://food.ec.europa.eu

4. U.S. Food and Drug Administration. (2023). Approved drug products with therapeutic equivalence evaluations, Orange Book. https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book

5. United States Patent and Trademark Office. (n.d.). Patent term adjustment and patent term. https://www.uspto.gov/patents/laws/patent-term-adjustment

6. Sisterna B.V. (n.d.). Sucrose esters and sucrose esters applications. https://www.sisterna.com

7. Mitsubishi Chemical Group. (n.d.). Sucrose ester and specialty materials products. https://www.mitsubishichemical.com